Printer Friendly

Use of site directed mutagenesis to analyze function of an anti-HIV Tat ribozyme.

Acquired immune deficiency syndrome (AIDS) is caused by a retrovirus called the Human Immunodeficiency Virus (HIV-1). By 1992, AIDS was the leading cause of death in the US among men aged 22-44 and by January 2000 approximately sixteen million people worldwide had died from this disease. It is estimated 35 million people are living with HIV/AIDS. Current therapies are dedicated to suppressing or inhibiting viral infection of its primary target cell: CD4+ T lymphocytes. These drug therapies do not destroy previously infected cells and are therefore are not curative. It may be possible to use gene therapy to modify target cells and render them resistant to HIV infection. We are currently studying the use of ribozymes as anti-HIV agents. Ribozymes are small catalytic RNAs that specifically cleave single stranded RNA targets. We have designed a hammerhead ribozyme that targets HIV-1 Tat mRNA. Tat is a small virally encoded protein that is responsible for regulation of HIV-1 transcription. Furthermore, Tat interacts directly with its target sequence within the HIV-1 LTR and is therefore critical for viral replication. An anti-Tat ribozyme was synthesized and cloned into both prokaryotic and eukaryotic expression vectors. Initial in vitro testing will be followed by ribozyme analysis in tissue culture models.
Cindy Hollingshead, Dr. William Jackson
Department of Biology-Geology
University of South Carolina, Aiken
COPYRIGHT 2002 South Carolina Academy of Science
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Hollingshead, Cindy; Jackson, William
Publication:Bulletin of the South Carolina Academy of Science
Article Type:Brief Article
Geographic Code:1USA
Date:Jan 1, 2002
Words:218
Previous Article:Geologic factors affecting delta formation: a small-scale physical model approach.
Next Article:Utilization of gold nanoparticles for the detection of lithium.
Topics:


Related Articles
High-tech gene therapy to target HIV.
Inner strength: gene therapy aims to build cells that thwart HIV replication.
The cloning of hammerhead ribozymes for analysis as anti-HIV-1 gene therapy agents. (South Carolina Academy of Sciences Abstracts).
Design and cloning of an anti-HIV-1 Tat hammerhead ribozyme. (Withdrawn).
Analysis of anti-HIV-1 Tat hammerhead ribozyme catalytic activity. (Withdrawn).
Design and cloning of hammerhead ribozymes targeted to NL43 HIV-1 Vif MRNA.
Design and cloning of a hammerhead ribozyme targeted to HIV-1 VPU.
Design and cloning of an anti HIV-1 Rev hammerhead ribozyme.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters